Reporter brief
Dasatinib plus quercetin combination tested in open-label pilot for aging markers in depression or schizophrenia.
What happened
This pilot open-label study examined dasatinib plus quercetin, a combination selected for senolytic properties, in older individuals with depression or schizophrenia. The study assessed effects on physiological aging markers. No results, effect sizes, or sample size details were reported in the abstract.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Other; Human.
Not recorded.
- Design
- Other
- Sample
- —
- Journal
- Washington University School of Medicine
- Published
- Apr 21, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.